The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1577
ISSUE 1577
July 29, 2019
Cladribine (Mavenclad) for Multiple Sclerosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
July 29, 2019 (Issue: 1577)
The FDA has approved cladribine (Mavenclad – EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of MS. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of MS.
... more
- Drugs for multiple sclerosis. Med Lett Drugs Ther 2016; 58:71.
- A Rae-Grant et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018; 90:789.
- Ocrelizumab (Ocrevus) for MS. Med Lett Drugs Ther 2017; 59:98.
- V Hamidi et al. A multiple treatment comparison of eleven disease-modifying drugs used for multiple sclerosis. J Clin Med Res 2018; 10:88.
- Siponimod (Mayzent) – a new drug for multiple sclerosis. Med Lett Drugs Ther 2019; 61:70.
- BM Jacobs et al. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry 2018; 89:1266.
- B Ceronie et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol 2018; 265:1199.
- G Giovannoni et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362:416.
- R Hermann et al. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. Br J Clin Pharmacol 2019; 85:1484.
- R Hermann et al. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet 2019; 58:283.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. July 5, 2019. Reprinted with permission by First Databank, Inc. All rights reserved. ©2019. www.fdbhealth. com/policies/drug-pricing-policy.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Cladribine (Mavenclad) for Multiple Sclerosis
Article code: 1577d
Electronic, downloadable article - $45
Article code: 1577d
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian